Skip to main content

Table 4 Areas under the curve of the calculated variables of model predicting the presence of PCa or csPCa in the validation cohort (chi-square test)

From: Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer

 

PCa

P value (compared to model)

csPCa

P value (compared to model)

Predictors

AUC (95% CI)

AUC (95% CI)

Model

0.845 (0.786–0.904)

 

0.834 (0.787–0.882)

 

Age

0.650 (0.566–0.735)

0.001

0.646 (0.560–0.732)

0.002

PSAD*10

0.762 (0.686–0.837)

< 0.001

0.769 (0.689–0.848)

< 0.001

PIRADs v2 (threshold 4)

0.798 (0.725–0.871)

< 0.001

0.777 (0.704–0.850)

< 0.001

PIRADs v2 (threshold 3)

0.687 (0.602–0.772)

< 0.001

0.667 (0.585–0.750)

< 0.001

  1. PCa prostate cancer, csPCa clinically significant prostate cancer; prostate-specific antigen, PSAD prostate-specific antigen density, PIRADS v2 Prostate Imaging Reporting and Data System version 2, AUC area under the curve